ESMO 2022 | SWOG S1801: Benefits of neoadjuvant immunotherapy for patients with resectable melanoma

Sapna Patel, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, talks on SWOG S1801 (NCT03698019), a randomised Phase II trial, with advanced, resectable melanoma. 345 patients were enrolled in the trial and were randomised to either the adjuvant arm (surgery followed by 18 doses of pembrolizumab), or the neoadjuvant arm (3 doses of pembrolizumab, then surgery, then 15 doses of pembrolizumab). The primary endpoint of the study was event-free survival (EFS). After a median follow-up of 14.7 months, EFS was significantly longer in the neoadjuvant arm compared to the adjuvant arm. Dr Patel highlights the potentially practice-changing impact of these results, as well as discussing the importance of designing clinical trials which involve community oncology centres, not just large academic research centres. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.